TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05121285

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Delivery of contrast fluid by lower GI endoscopy
Description: Each participant will receive one delivery of 440 ml contrast fluid by lower GI endoscopy to the cecum of the colon. The participants perform a bowel lavage using Sodiumpicosulphate/Magnesiumcitrate (Picoprep, Ferring) 24 hours before the delivery of contrast fluid. An colon X-ray is obtained within 10 minutes after the contrast fluid is delivered. The participants is in a supine position fram delivery and until the colon x-ray is obtained.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Delivery of contrast fluid by enema with and without positioning
Description: Each participant will receive one delivery of 440 ml contrast fluid by enema. The participants perform a bowel lavage using Sodiumpicosulphate/Magnesiumcitrate (Picoprep, Ferring) 24 hours before the delivery of contrast fluid. The enema procedure includes:~1. The participant lies on his/her left side in neutral position when the enema is delivered~2. X-ray of the colon is obtained with the participant lying on his/her back.~3. The participant is positioned back to his/her left sided position and tilted in a Trendelenburg position. The position is held for two minutes~4. The participant is turned to an abdominal position while the bed remains tilted in Trendelenburg position.~5. Participant turne to the right side. When positioned the bed is tilted the opposite way (anti-Trendelenburg.) The position is held for two minutes.~6. A second colon X-ray is obtained after the participants has rested for ten minutes in a supine neutral position
Study: NCT03824756

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NGO supported GMP program
Description: An International NGO has signed a contract with Government to support in implementing the growth Monitoring and Promotion (GMP) program. This program will be implemented at Community clinics. It will ensure the sustainability of community clinics in the selected areas through capacity building and follow up with community groups, community support groups, and Government Health and Family Planning service providers.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-supported GMP program
Description: This is control arm of the study. In this arm, there will be Government's usual GMP program implemented at community clinics without any NGO support.
Study: NCT04833972

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey questionnaire
Description: Each version of the questionnaire has the same questions about perceived norms about substance use in the community but differs in how the response options are offered.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey questionnaire
Description: Each version of the questionnaire has the same questions about perceived norms about substance use in the community but differs in how the response options are offered.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey questionnaire
Description: Each version of the questionnaire has the same questions about perceived norms about substance use in the community but differs in how the response options are offered.
Study: NCT05341609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JT001
Description: Day 1: 600mg, Q12H X 1 day; Day 2\~5: 300mg, Q12H X 4 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paxlovid
Description: Day 1\~5: 300 mg of Nirmatrelvir and 100 mg of ritonavir, Q12H X 5 days
Study: NCT05458453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: Self-controlled intravenous analgesia pump was used for continuous injection, and it was prepared according to sufentanil 1.5ug/ml+ esketamine 0.75ug/ml+16mg ondansetron. After the operation, the analgesic pump was connected, and sufentanil 0.1ug/kg/h+ esketamine 0.05mg/kg/h was pumped continuously for 24 hours. The continuous infusion of analgesia pump is (kg body weight/15) ml/h. (e.g. 60kg, pump speed 4ml/h, total amount 96ml).
Study: NCT05241925

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation, exercise
Description: Combined training (continuous aerobic + resistance) The protocol will consist of supervised exercise lasting 1h10min each session (5 min of warm-up, 30 min of aerobic exercise, 30 min of resistance exercise and 5 min of cool-down/relaxation).~Combined training (high-intensity interval (IAI) + resistance) - Supervised exercise lasting 30 min each session (5 min warm-up, 20 min IAI and 5 min cool-down/relaxation).~And Resistance Training~- Resistance exercise will be performed at 70-80% of one repetition maximum (1-RM); 2 to 3 sets of 8 to 12 repetitions. The main muscle groups will be trained using training equipment with free weights and body mass of the participants. Exercises included leg extension, seated bicep curl, squat, seated triceps extension, sit-up, seated shoulder press, and standing pulldown

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation, exercise
Description: Combined training (continuous aerobic + resistance) The protocol will consist of supervised exercise lasting 1h10min each session (5 min of warm-up, 30 min of aerobic exercise, 30 min of resistance exercise and 5 min of cool-down/relaxation).~Combined training (high-intensity interval (IAI) + resistance) - Supervised exercise lasting 30 min each session (5 min warm-up, 20 min IAI and 5 min cool-down/relaxation).~And Resistance Training~- Resistance exercise will be performed at 70-80% of one repetition maximum (1-RM); 2 to 3 sets of 8 to 12 repetitions. The main muscle groups will be trained using training equipment with free weights and body mass of the participants. Exercises included leg extension, seated bicep curl, squat, seated triceps extension, sit-up, seated shoulder press, and standing pulldown
Study: NCT06420440

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hepatic arterial infusion chemotherapy
Description: Patients in the neoadjuvant group received two cycles of neoadjuvant hepatic arterial infusion chemotherapy (HAIC, adoption of the FOFOLX6 program, Folinic acid+5-fluorouracil+Oxaliplatin, 21 days between second HAIC treatments with a window of ±3 days)
Study: NCT06464523

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Face to face education
Description: In addition to the standard cervical cancer screening programme service, participants in this group received individual face-to-face health education on HPV and cervical cancer prevention through home visits and were given educational brochures. Participants in this group were interviewed a total of four times (four times face-to-face) during the research period.
Study: NCT06123936

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reminder
Description: At mid-campaign, GPs in the interventional arm will recall their patients to be vaccinated via the reminder module Eo software~* This recall will be carried out as follows: patients whose medical records include a number likely to receive telephone text messages will be recalled by this means Two generic messages that doctors can choose will be proposed by the call-back module integrated into the Eo medical software~* In addition, the recall module will offer to send a postal letter with the same content as the text message to patients who do not have a mobile phone number in the business software but do have a postal address~* The recall module will also provide the doctor with a list of patients who have neither a mobile phone number or a postal address, so that he can recall them to be vaccinated orally by landline telephone or in consultation when they next visit.~The type of recall and the date of it will be notified in the medical file of each patient.
Study: NCT06420440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Patients in the neoadjuvant therapy group received Lenvatinib before surgery(Len was started before HAIC treatment, discontinued during HAIC treatment, and discontinued approximately two weeks before surgery, Oral 8 mg or 12mg once a day depending body weight).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Patients in the neoadjuvant therapy group received two cycles of Tislelizumab therapy before surgery (First treatment with Tislelizumab was started 0-1 days after HAIC, 200 mg IV, followed by a second treatment 21 days later)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Liver resection
Description: Patients in the neoadjuvant therapy group were evaluated for tumor status and surgical safety after neoadjuvant therapy, and eligible patients subsequently underwent surgical resection. Patients in the direct surgery group underwent liver resection.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver resection
Description: Patients in the neoadjuvant therapy group were evaluated for tumor status and surgical safety after neoadjuvant therapy, and eligible patients subsequently underwent surgical resection. Patients in the direct surgery group underwent liver resection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tislelizumab
Description: Given the high risk of postoperative recurrence, patients in both groups received adjuvant Tis therapy (every 21 days for 8 cycles) starting about one month after surgery.
Study: NCT06464523

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online education
Description: In addition to the standard cervical cancer screening programme service, participants in this group received individual health education on HPV and cervical cancer prevention online via video call via WhatsApp application and were given a digital education brochure. Participants in this group were interviewed a total of four times (four times remotely) during the research process.
Study: NCT06420440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Given the high risk of postoperative recurrence, patients in both groups received adjuvant Tis therapy (every 21 days for 8 cycles) starting about one month after surgery.
Study: NCT05968807

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iParent2Parent Program
Description: iParent2Parent is an online peer support mentorship program that is based on the iPeer2Peer online peer support mentorship program, which has been established in multiple chronic disease populations as a self-management intervention, including in chronic pain and juvenile idiopathic arthritis populations. The iParent2Parent program connect parents one-to-one with other parents of pediatric solid organ transplant (SOT) recipients who are trained to offer vital peer support and mentorship.
Study: NCT06475482

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lip hydrant
Description: lip hydrant containing peppermint oil, perilla frutescens, and Emblica fruit extract or petroleum gel.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Petroleum gel
Description: Vaseline
Study: NCT06308120

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ion Endoluminal System
Description: Participants in the test arm will undergo a diagnostic bronchoscopy with ION™ Endoluminal System.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: superDimension Navigation System and Accessories
Description: Participants in the control arm will undergo a diagnostic bronchoscopy with superDimension Navigation System and Accessories.
Study: NCT04900688

Intervention type: DEVICE
Group type: OTHER
Intervention: LithoVue Elite
Description: LithoVue Elite is a disposable flexible ureteroscope that offer novel pressure sensory capacity
Study: NCT05606991

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CPAP Withdrawal
Description: Complete withdrawal of continuous positive airway pressure (CPAP) therapy for a 2-week period.
Study: NCT06256718

Intervention type: OTHER
Group type: OTHER
Intervention: Educational Intervention
Description: Evidence-based strategy (PC TEACH)
Study: NCT06245590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin
Description: 20 grams/ week Albumin + Midodrine (5mg thrice daily and will be increased every 3 days upto 15 mg thrice daily with target MAP (\>75 mm and \<90).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midodrine
Description: Midodrine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midodrine
Description: Midodrine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of Care
Study: NCT04096625

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS
Description: Active tDCS will be delivered at 2mA for 20 minutes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Active tDCS
Description: Active tDCS will be delivered at 2mA for 20 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assertiveness Training Program (ATP)
Description: The Assertiveness Training Program (ATP) is a cognitive-behavioural therapy delivered in group sessions.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Assertiveness Training Program (ATP)
Description: The Assertiveness Training Program (ATP) is a cognitive-behavioural therapy delivered in group sessions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham tDCS
Description: Sham tDCS, after 40 seconds of stimulation (2mA), a small current pulse was delivered every 550 msec (110 muA over 15 msec).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: Sham tDCS, after 40 seconds of stimulation (2mA), a small current pulse was delivered every 550 msec (110 muA over 15 msec).
Study: NCT04778579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARI-0001 cells
Description: Adult differentiated autologous T-cells from peripheral blood, expanded and transduced with a lentivirus to express a chimeric antigen receptor with anti-CD19 specificity (A3B1) conjugated with the co-stimulatory regions 4-1BB and CD3z
Study: NCT06163261

Intervention type: OTHER
Group type: OTHER
Intervention: Physical activity
Description: The intervention group will receive an individualized and person-centred prescription of physical activity and exercise.
Study: NCT05986162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itolizumab
Description: Patients to be treated with Itolizumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itolizumab
Description: Patients to be treated with Itolizumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itolizumab
Description: Patients to be treated with Itolizumab.
Study: NCT04733092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipiodol
Description: Lipiodol in emulsion with contrast agent
Study: NCT04886050

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LC350189 Tablet
Description: Subject will receive an LC350189 Tablet as single dose on Day 1 or Day 5

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LC350189 Capsule
Description: Subject will receive an LC350189 Capsule as single dose on Day 1 or Day 5
Study: NCT05851950

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: group rumination focused cognitive behavioural therapy
Description: Psychotherapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: opus treatment
Study: NCT05109507

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visitor Mindset
Description: Single-session, self-guided intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxing with Nature
Description: Single-session, self-guided intervention
Study: NCT05149846

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Pre-conditioning
Description: Pre-conditioning by three consecutive 60 seconds balloon inflations, spaced 120 seconds apart followed by 10 minutes rest prior to PCI
Study: NCT05744947

Intervention type: OTHER
Intervention: Data collection
Description: Specific Readapt -DISCO complementary questionnaire rehabilitation
Study: NCT04907383

Intervention type: OTHER
Intervention: quality of life
Description: QoL assessment
Study: NCT04740541

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intakes (Reference protein drinks (Scandishake, Solcarb, Beneprotein) and cookies)
Description: Reference protein drinks (Scandishake, Solcarb, Beneprotein) and cookies to meet nutritional requirements, 5 levels of threonine intakes
Study: NCT06092177

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periodontal surgery with virtual reality distraction
Description: Periodontal surgery to improve gingival contour and eliminate inflamed periodontal pockets

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periodontal surgery without virtual reality distraction
Description: Periodontal surgery to improve gingival contour and eliminate inflamed periodontal pockets
Study: NCT05466786

Intervention type: OTHER
Intervention: Standard Management
Description: Standard Management
Study: NCT04288869

Intervention type: OTHER
Intervention: Continuous monitoring of arterial blood pressure
Description: For all patients, mean arterial pressure (unit mmHg) will be collected over three distinct periods: 1) baseline or during pre-oxygenation at FiO2 of 21% in awake patients, 2) before orotracheal intubation, and 3) just after mechanical ventilation.

Intervention type: OTHER
Intervention: Transcranial Doppler
Description: Measurement of cerebral blood flow velocity (CFV) with use of Transcranial Doppler ultrasonography.~For all patients, CFV (unit cm/s) will be collected over three distinct periods: 1) baseline or during pre-oxygenation at FiO2 of 21% in awake patients, 2) before orotracheal intubation, and 3) just after mechanical ventilation.

Intervention type: OTHER
Intervention: Bispectral Index (BIS)
Description: Continuous measurement of burst suppression (BS; %) with use of Bispectral Index (BIS).~For all patients, BS will be collected over three distinct periods: 1) baseline or during pre-oxygenation at FiO2 of 21% in awake patients, 2) before orotracheal intubation, and 3) just after mechanical ventilation

Intervention type: OTHER
Intervention: Near-infrared spectroscopy
Description: Continuous measurement of cerebral oxygen saturation (SO2) with Near-infrared spectroscopy (NIRS).~For all patients, SO2 (%) will be collected over three distinct periods: 1) baseline or during pre-oxygenation at FiO2 of 21% in awake patients, 2) before orotracheal intubation, and 3) just after mechanical ventilation.
Study: NCT05210985

Intervention type: BEHAVIORAL
Intervention: Affordances in the Home Environment for Motor Development-Infant Scale
Description: Affordances in the Home Environment for Motor Development-Infant Scale is a parent-filled assessment to determine the nature and amount of factors affecting infant motor skill development in the home environment, including the availability of toys, materials, and the availability of spaces.

Intervention type: BEHAVIORAL
Intervention: Peabody Developmental Motor Scales-2
Description: Peabody Developmental Motor Scales \| Second Edition (PDMS-2) combines in-depth assessment with training or remediation of gross and fine motor skills of children from birth through 5 years.

Intervention type: BEHAVIORAL
Intervention: Test Of Sensory Functions In Infants (Tsfı)
Description: This test helps you identify infants with sensory integrative dysfunction-including those at risk for developing learning disabilities as they grow older. The TSFI provides objective criteria that allow you to determine whether, and to what extent, an infant has deficits in sensory functioning. Designed for use with children from 4 months to 18 months old, the TSFI provides an overall measure of sensory processing and reactivity, as well as scores on the following subdomains: Reactivity to Tactile Deep Pressure Visual Tactile Integration Adaptive Motor Function Ocular Motor Control Reactivity to Vestibular Stimulation
Study: NCT06506357

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Good Girl Probiotics
Description: Participants will take one capsule of the Good Girl Probiotics supplement daily in the morning for eight weeks.
Study: NCT05195112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT921
Description: Active ingredient

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline
Study: NCT05674253

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine + Hydrocortisone
Description: Patients will receive dexmedetomidine 0.7 ɥg/kg/hr IV infusion before aortic cross-clamping, and will be continued intra-operatively and in ICU till weaning from mechanical ventilation Patients also will also receive Hydrocortisone 100 mg intravenous (IV) before aortic cross-clamping then 100 mg every 8 hours after surgery which will be continued for 48 hours
Study: NCT05120505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: The patients in this group will be obtain Metformin starting from 50mg everyday at night, and gradually increase to maximum tolerable dose of 1-2g per day according to weights of patients for 6 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The patients in this group will be obtain starch tablets (which had same appearance and size comparing to Metformin) starting from 50mg everyday to 1-2g per day according to weights of patients for 6 months.
Study: NCT06500104

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Kefir peptide
Description: Dosage: 1.2 gram kefir peptide daily oral intake for 12 weeks
Study: NCT06004375

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Neomune
Description: Neomune containing 4.8 g arginine and 2 g glutamine

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Neomune
Description: Neomune containing 4.8 g arginine and 2 g glutamine
Study: NCT04934436

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sleeping glasses and earplug
Description: In this study, the effect of the chronotype-appropriate nursing care on the intervention group will be examined.
Study: NCT06164288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Amniotic Epithelial Stem Cell Injection
Description: The dose escalation is carried out according to the 3+3 ascending principle, and a total of 3 dose levels are set:~1. Dose Level 1: 1×106 cells/kg;~2. Dose Level 2: 2×106 cells/kg;~3. Dose Level 3: 3×106 cells/kg; Note: In this study, if the maximum tolerated dose (MTD) is not explored at dose level 3 (3×106 cells/kg), it will be discussed by the Safety Review Committee (SRC) to decide whether to proceed with further dose escalation or expansion to 6 patients.
Study: NCT05592132

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality headset
Description: Each patient in this treatment group will use a virtual reality headset during 3 procedures. During each procedure, the pain level will be assessed and compared with the assessed group.
Study: NCT04314219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide 50mg
Description: Cyclophosphamide as GVHD prophylaxis will be on day +3 and day +5

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Methotrexate as GVHD prophylaxis will be on day +1, day +3, and day +6